Clinical Trials Browser

Phase 1 × Carcinoma × dacomitinib × Clear all

NCT00728390 2024-04-22

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Phase 1 Completed

Carcinoma, Neoplasm Metastasis